Clinical usefulness of bone turnover marker concentrations in osteoporosis

TY - JOUR

T1 - Clinical usefulness of bone turnover marker concentrations in osteoporosis

AU - Morris, H A

AU - Eastell, R

AU - Jorgensen, N R

AU - Cavalier, E

AU - Vasikaran, S

AU - Chubb, S A P

AU - Kanis, J A

AU - Cooper, C

AU - Makris, K

AU - IFCC-IOF Working Group for Standardisation of Bone Marker Assays (WG-BMA)

N1 - Copyright © 2016 Elsevier B.V. All rights reserved.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Current evidence continues to support the potential for bone turnover markers (BTM) to provide clinically useful information particularly for monitoring the efficacy of osteoporosis treatment. Many of the limitations identified earlier remain, principally in regard to the relationship between BTM and incident fractures. Important data are now available on reference interval values for CTX and PINP across a range of geographic regions and for individual clinical assays. An apparent lack of comparability between current clinical assays for CTX has become evident indicating the possible limitations of combining such data for meta-analyses. Harmonization of units for reporting serum/plasma CTX (ng/L) and PINP (μg/L) is recommended. The development of international collaborations continues with an important initiative to combine BTM results from clinical trials in osteoporosis in a meta-analysis and an assay harmonization program are likely to be beneficial. It is possible that knowledge derived from clinical studies can further enhance fracture risk estimation tools with inclusion of BTM together with other independent risk factors. Further data of the relationships between the clinical assays for CTX and PINP as well as physiological and pre-analytical factors contributing to variability in BTM concentrations are required.

AB - Current evidence continues to support the potential for bone turnover markers (BTM) to provide clinically useful information particularly for monitoring the efficacy of osteoporosis treatment. Many of the limitations identified earlier remain, principally in regard to the relationship between BTM and incident fractures. Important data are now available on reference interval values for CTX and PINP across a range of geographic regions and for individual clinical assays. An apparent lack of comparability between current clinical assays for CTX has become evident indicating the possible limitations of combining such data for meta-analyses. Harmonization of units for reporting serum/plasma CTX (ng/L) and PINP (μg/L) is recommended. The development of international collaborations continues with an important initiative to combine BTM results from clinical trials in osteoporosis in a meta-analysis and an assay harmonization program are likely to be beneficial. It is possible that knowledge derived from clinical studies can further enhance fracture risk estimation tools with inclusion of BTM together with other independent risk factors. Further data of the relationships between the clinical assays for CTX and PINP as well as physiological and pre-analytical factors contributing to variability in BTM concentrations are required.

KW - Biomarkers/metabolism

KW - Bone Remodeling

KW - Humans

KW - Osteoporosis/metabolism

KW - Osteoporotic Fractures/metabolism

KW - Reference Standards

KW - Risk Assessment

U2 - 10.1016/j.cca.2016.06.036

DO - 10.1016/j.cca.2016.06.036

M3 - Review

C2 - 27374301

SN - 0009-8981

VL - 467

SP - 34

EP - 41

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

ER -